{"owner": "ArrayExpress Uploader", "pop_total": 0, "id": 4051, "factors": [{"GSM709764": {"KNOCKDOWN": "SRC-1 scrambled", "TREATMENT": "tamoxifen for 120 min"}}, {"GSM709765": {"KNOCKDOWN": "SRC-1 siRNA", "TREATMENT": "untreated"}}, {"GSM709764": {"KNOCKDOWN": "SRC-1 scrambled", "TREATMENT": "tamoxifen for 120 min"}}, {"GSM709767": {"KNOCKDOWN": "SRC-1 siRNA", "TREATMENT": "tamoxifen for 120 mins"}}, {"GSM709764": {"KNOCKDOWN": "SRC-1 scrambled", "TREATMENT": "tamoxifen for 120 min"}}, {"GSM709769": {"KNOCKDOWN": "SRC-1 siRNA", "TREATMENT": "tamoxifen for 120 min"}}, {"GSM709770": {"KNOCKDOWN": "SRC-1 scrambled", "TREATMENT": "untreated"}}, {"GSM709765": {"KNOCKDOWN": "SRC-1 siRNA", "TREATMENT": "untreated"}}, {"GSM709765": {"KNOCKDOWN": "SRC-1 siRNA", "TREATMENT": "untreated"}}, {"GSM709770": {"KNOCKDOWN": "SRC-1 scrambled", "TREATMENT": "untreated"}}, {"GSM709770": {"KNOCKDOWN": "SRC-1 scrambled", "TREATMENT": "untreated"}}, {"GSM709765": {"KNOCKDOWN": "SRC-1 siRNA", "TREATMENT": "untreated"}}, {"GSM709770": {"KNOCKDOWN": "SRC-1 scrambled", "TREATMENT": "untreated"}}, {"GSM709764": {"KNOCKDOWN": "SRC-1 scrambled", "TREATMENT": "tamoxifen for 120 min"}}], "ownerprofile_id": "arrayexpress_sid", "platform": 4, "summary_wrapped": "The development of breast cancer resistance to endocrine therapy results from an increase in cellular plasticity leading to the...", "pubmed_id": 22072566, "geo_gse_id": "E-GEOD-28645", "owner_profile": "/profile/8773/arrayexpressuploader", "factor_count": 2, "sample_count": 14, "tags": ["breast", "breast cancer", "cancer", "estrogen", "protein"], "lastmodified": "Dec.12, 2014", "is_default": false, "geo_gds_id": "", "slug": "src1-gene-regulation-in-endocrine-resistant-breast", "geo_id_plat": "E-GEOD-28645_A-AFFY-44", "name": "SRC1 gene regulation in endocrine resistant breast cancer cells", "created": "Sep.16, 2014", "summary": "The development of breast cancer resistance to endocrine therapy results from an increase in cellular plasticity leading to the development of a steroid independent tumour.  The p160 steroid coactivator protein SRC-1, through interactions with developmental proteins and other non-steroidal transcription factors drives this tumour adaptability.  Here, using discovery studies we identify ADAM22, a non-protease member of the ADAMs family, as a direct target of SRC-1, independent of estrogen receptor(ER). Molecular, cellular, in vivo and clinical studies confirmed SRC-1 as a regulator of ADAM22 and established a role for ADAM22 in endocrine resistant tumour progression.  ADAM22 has the potential to act as a therapeutic drug target and a companion predictive biomarker in the treatment of endocrine resistant breast cancer. 14 samples representing 4 conditions were analysed. Samples were transfected with either a siRNA targetting SRC1 or a control scrambled siRNA. Samples were subject to tamoxifen treatment or untreated.", "source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-28645", "species": "human", "sample_source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-28645/samples/"}